top button
    Got Questions


Global IoT Summit 2018
Oct 31, 2018
The Leela Palace, Bangalore



    Connect to us
      Facebook Login
      Site Registration Why to Join

Facebook Login
Site Registration

Pulmonary Arterial Hypertension (PAH) Market Forecast Incredible Potential Examined in New Research Report

0 votes
10 views

In a recent report by Transparency Market Research (TMR), the vendor landscape for global pulmonary arterial hypertension (PAH) market is highly opportunistic. Since PAH has no permanent cure, the market is gaining popularity. A key factor to boost the growth of the PAH market is the availability of several treatment options for slowing down the spreading of the diseases, control symptoms, and enhancing the quality of life of patients.

Some of the leading players of the global market for PAH are United Therapeutics Corp., Novartis International AG, Pfizer Inc., Gilead Sciences Inc., and GlaxoSmithKline Plc. The key drugs available in the global market are PDE-5 inhibitors, ERAs, prostacyclin analogs, sGC stimulators, and Prostacyclin with ERAs contributing larger shares for revenue. 

As per the TMR report, the global pulmonary arterial hypertension market is estimated to exhibit an impressive CAGR of 17.90% within the forecast period of 2014 to 2020. The value is presumed to be at US$5.19 bn by the end of the forecast period. North America is anticipated to account for a king’s share during the forecast period followed by Europe. This is due to the high awareness about PAH treatments available that drives the growth of the market in both the regions.

Get Sample with Latest Research @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1181

Asia Pacific to Witness Stable Growth with Increase in Preference for Generic Drugs  

The market is receiving a significant boost with the existence of promising pipelines and effective drugs approvals in present times. This is also acting as a primary factor in the growth and development of the pulmonary arterial hypertension market. The government is also taking active initiatives that are acting in favor of the PAH market growth.

According to a TMR, the license expiry of some blockbuster drugs are making way for generic drugs penetration. The increased sales of generic drugs adversely affect the overall revenue generation of the market since it is 70 to 80 per cent cheaper as compared to branded drugs. Cutting-edge therapies are developed for treating PAH. Therefore the future of pulmonary arterial hypertension market is presumed to be brighter in the years to come.

The market in Asia Pacific region is also presumed to be highly opportunistic in nature because of countries like China, Australia, Japan, New Zealand, and India, that has high growth rates. These emerging nations are estimated to be major global players in the future years.

Buy Now Pulmonary Arterial Hypertension (PAH) Market Forecast Research Report @ https://www.transparencymarketresearch.com/checkout.php?rep_id=1181&ltype=S

Patent Expiry of PAH Drug Remedies Affecting Market Growth in Negative Light

Pulmonary arterial hypertension does not have a permanent cure. Medications may only help to decrease the speed by which the disease spreads into the body. In most developing countries, people are unaware of the treatment. This acts as a hindrance in the growth of the PAH market. Apart from that, high cost of such remedies and license expiry may also add as barrier in the growth and development of PAH in the market.

However, the global PAH market is anticipated to see growth in the coming years due to a number of factors like increase in the number of obese population, rise in the healthcare expenses, and ageing population. Growing population of women and their rising health complexities also gives way to PAH market for growth since PAH mostly result from high blood pressure in the lungs. This may further lead to other diseases like obstructive sleep apnea (OSA), and diastolic heart failure, hence creating vast opportunities for PAH market to grow. The key trends in this market are consumption of junk food items, continuous support provided by the government and increase in the number of cardiovascular diseases.

More Trending Reports by Transparency Market Research –

Hearing Aids Market: prnewswire.com/news-releases/hearing-aids-market-increasing-prevalence-of-hearing-loss-worldwide-augments-product-demand-says-tmr-300857268.html

Viral Vector and Plasmid DNA Manufacturing Market: globenewswire.com/news-release/2019/04/30/1812834/0/en/Viral-Vector-and-Plasmid-DNA-Manufacturing-Market-is-anticipated-to-surpass-US-2-Billion-by-2027-TMR.html

posted Feb 13 by Bella Watson

  Promote This Article
Facebook Share Button Twitter Share Button Google+ Share Button LinkedIn Share Button Multiple Social Share Button

Related Articles
0 votes

In a recent report by Transparency Market Research (TMR), the vendor landscape for global pulmonary arterial hypertension (PAH) market is highly opportunistic. Since PAH has no permanent cure, the market is gaining popularity. A key factor to boost the growth of the PAH market is the availability of several treatment options for slowing down the spreading of the diseases, control symptoms, and enhancing the quality of life of patients.

Some of the leading players of the global market for PAH are United Therapeutics Corp., Novartis International AG, Pfizer Inc., Gilead Sciences Inc., and GlaxoSmithKline Plc. The key drugs available in the global market are PDE-5 inhibitors, ERAs, prostacyclin analogs, sGC stimulators, and Prostacyclin with ERAs contributing larger shares for revenue.

As per the TMR report, the global pulmonary arterial hypertension market is estimated to exhibit an impressive CAGR of 17.90% within the forecast period of 2014 to 2020. The value is presumed to be at US$5.19 bn by the end of the forecast period. North America is anticipated to account for a king’s share during the forecast period followed by Europe. This is due to the high awareness about PAH treatments available that drives the growth of the market in both the regions.

Asia Pacific to Witness Stable Growth with Increase in Preference for Generic Drugs  

The market is receiving a significant boost with the existence of promising pipelines and effective drugs approvals in present times. This is also acting as a primary factor in the growth and development of the pulmonary arterial hypertension market. The government is also taking active initiatives that are acting in favor of the PAH market growth.

Get Sample with Latest Research @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1181

According to a TMR, the license expiry of some blockbuster drugs are making way for generic drugs penetration. The increased sales of generic drugs adversely affect the overall revenue generation of the market since it is 70 to 80 per cent cheaper as compared to branded drugs. Cutting-edge therapies are developed for treating PAH. Therefore the future of pulmonary arterial hypertension market is presumed to be brighter in the years to come.

The market in Asia Pacific region is also presumed to be highly opportunistic in nature because of countries like China, Australia, Japan, New Zealand, and India, that has high growth rates. These emerging nations are estimated to be major global players in the future years.

Patent Expiry of PAH Drug Remedies Affecting Market Growth in Negative Light

Pulmonary arterial hypertension does not have a permanent cure. Medications may only help to decrease the speed by which the disease spreads into the body. In most developing countries, people are unaware of the treatment. This acts as a hindrance in the growth of the PAH market. Apart from that, high cost of such remedies and license expiry may also add as barrier in the growth and development of PAH in the market.

However, the global PAH market is anticipated to see growth in the coming years due to a number of factors like increase in the number of obese population, rise in the healthcare expenses, and ageing population. Growing population of women and their rising health complexities also gives way to PAH market for growth since PAH mostly result from high blood pressure in the lungs. This may further lead to other diseases like obstructive sleep apnea (OSA), and diastolic heart failure, hence creating vast opportunities for PAH market to grow. The key trends in this market are consumption of junk food items, continuous support provided by the government and increase in the number of cardiovascular diseases.

More Trending Reports by Transparency Market Research –

In-vitro Colorectal Cancer Screening Tests Market: globenewswire.com/news-release/2019/02/21/1739306/0/en/In-vitro-Colorectal-Cancer-Screening-Tests-Market-to-Hit-US-980-6-Mn-by-2026-Owing-to-High-Diagnostic-Accuracy-TMR.html

Cancer Immunotherapy Market: globenewswire.com/news-release/2019/04/15/1803955/0/en/Cancer-Immunotherapy-Market-to-attain-a-value-of-US-124-88-billion-by-2024-TMR.html

0 votes

Transparency Market Research (TMR) has published a new report titled, “Parenteral Nutrition Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026”. According to the report, the global parenteral nutrition market was valued at US$ 5,299.5 Mn in 2017. It is projected to expand at a CAGR of 4.7% from 2018 to 2026. High prevalence of chronic disorders, rise in cases of malnutrition, and new product approvals are anticipated to drive the global market in the next few years.

North America is expected to dominate the global parenteral nutrition market during the forecast period, followed by Europe. High prevalence of malnutrition in hospitalized patients, increase in the geriatric population, and approvals of novel parenteral nutrition combination in the U.S. and Europe are likely to drive the parenteral nutrition market in these regions during the forecast period. The market in Asia Pacific is projected to expand at a high CAGR during the forecast period.

High prevalence and increase in incidence rate of chronic diseases to drive market

High prevalence and rise in incidence rate of chronic diseases across the globe is a key factor driving the global parenteral nutrition market. The rise in cancer, AIDS, diabetes, Crohn’s disease, gastro-intestinal disorders, and short bowel syndrome cases has also fuelled the consumption of parenteral nutrition in recent years. For instance, according to International Agency for Research on Cancer (IARC), around 18.1 million new cases and 9.6 million deaths are estimated to have occurred in 2018.

Request a PDF Sample https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=3611

Moreover, the National Kidney Foundation stated that around 10% of the world’s population is affected by chronic kidney disease each year. The Centers for Disease Control and Prevention also noted that more than 30 million people in the U.S. have chronic kidney disease in the year 2017. Thus, the high prevalence and substantial rise in incidence rate of chronic diseases across the globe is a key factor driving the global parenteral nutrition market.

Parenteral lipid emulsions to propel the parenteral nutrition market

The report offers a detailed segmentation of the global parenteral nutrition market based on different types of nutrition administered to the patients. Based on type of nutrition, the global market has been segmented into carbohydrates, parenteral lipid emulsions, single dose amino acid solutions, trace elements, electrolytes, & minerals, and vitamins. Infusion of lipid emulsions delivers high energy supply, facilitates the prevention of high glucose infusion rates, and is necessary for the supply of essential fatty acids. Expansion of the parenteral lipid emulsions segment is due to its potential benefits to use as a drug delivery vehicle.

For instance, administration of lipid emulsions act as essential drug carriers, which results in reduced pain, irritation, and prevention of thrombophlebitis. Moreover, lipid emulsions containing a mixture of medium and long chain triglycerides (MCT/LCT) have proven to be highly effective in critically-ill patients. This mixture of lipid emulsion does not hamper the functioning of the liver and causes minimal interference with pulmonary hemodynamics. According to the Society of Critical Care Medicine, 5.7 million patients are admitted to the intensive care unit in the U.S. every year. Most of these include critically-ill patients who need high level of acute care. Thus, rising number of critically-ill patients is likely to boost the lipid emulsions segment during the forecast period.

Asia Pacific offers high incremental opportunity

The parenteral nutrition market in Asia Pacific is projected to expand at a notable CAGR of 7.9% during the forecast period. High prevalence of chronic kidney disorders in highly populated countries, such as China and India, rapid improvement in health care infrastructure, increase in access to health care facilities, and rise in per capita health care expenditure in the region are likely to fuel the market in Asia Pacific during the forecast period. Large base of pharmaceutical companies in countries such as India, Japan, and China also drives the market in the region. Emerging economies and expansion of pharmaceutical markets in countries, such as China, India, Indonesia, Singapore, Taiwan, and Thailand are expected to propel the market in Asia Pacific. Rising cases of preterm birth, which leads to malnutrition, is a key reason fuelling the consumption of parenteral nutrition in Asia Pacific.

Buy Now Parenteral Nutrition Market Research Report @ https://www.transparencymarketresearch.com/checkout.php?rep_id=3611&ltype=S

Key trend of new product development and commercialization to strengthen parenteral nutrition product portfolio

The global parenteral nutrition market is highly consolidated, with a few global players accounting for a major share in respective regions. Leading players in parenteral nutrition are trying to seek approvals for their new parenteral nutrition formulations from concerned authorities, such as the U.S. FDA, in order to launch new products in the market. This effort is focused at both grabbing new market shares and providing for the deficit of parental nutrition in developing regions. The leading players shaping the vendor landscape of the global parenteral nutrition market are Sichuan Kelun Pharmaceutical Co., Ltd., Allergan plc (Actavis plc), Fresenius Kabi AG, Grifols S.A., Baxter International, Inc., Claris Lifesciences Limited, and B. Braun Melsungen AG, and Pfizer, Inc.

More Trending Reports by Transparency Market Research –

Liquid Biopsy Market: prnewswire.com/news-releases/liquid-biopsy-market-to-cross-us9071-7-million-by-2026—says-tmr-300864391.html

HIV/AIDS Diagnostics Market: prnewswire.com/news-releases/hivaids-diagnostics-market-to-touch-us5-74-billion-by-2025—says-tmr-300827872.html

0 votes

Alport Syndrome Market: Introduction

  • Alport syndrome is a rare genetic condition characterized by kidney disease, hearing loss, and eye abnormalities. This condition is caused by mutation in the genes COL4A3, COL4A4, and COL4A5, which are involved in the production of proteins such as type IV collagen. Patients suffering from Alport syndrome suffer from progressive loss of kidney function. Presence of blood in urine indicates abnormal functioning of the kidneys. A number of patients suffering from Alport syndrome develop high levels of proteins in the urine. As the condition progresses, the kidney function deteriorates leading to end-stage renal disease (ESRD).
  • People suffering from Alport syndrome experience inner ear abnormalities such as sensorineural hearing loss and vision loss. Eye abnormalities, hearing loss, and progressive kidney diseases are more common in men than women. Alport syndrome is quite rare and occurs in 1 in 50,000 newborns. Nearly 80% of Alport syndrome cases are caused by mutations in the COL4A5 gene located in the X chromosome.

Report Overview @ https://www.transparencymarketresearch.com/alport-syndrome-market.html

  • The other 15% of Alport syndrome cases is a result of mutations in the COL4A3 or COL4A4 genes. There is no cure for Alport syndrome; however, rich product pipeline promises effective treatment for the syndrome. Advanced diagnostic techniques for Alport syndrome are likely to help in the management of the symptoms and side effects.

Key Drivers and Restraints of Global Alport Syndrome Market

  • Alport syndrome is a major cause of kidney disease among the patient population. Rise in prevalence of genetic disorders is likely to augment the global Alport syndrome market. There is no cure for this syndrome. Hence, availability of drugs for the management of its symptoms such as high blood pressure is projected to boost the growth of the global market.
  • Demand for genetic testing as an effective diagnostic procedure for Alport syndrome is anticipated to drive the global Alport syndrome market. Moreover, skin biopsy and kidney biopsy are used for diagnosis of the early symptoms of Alport syndrome and faster adoption of these diagnostic techniques is a major factor propelling the global market.
  • High investments by the key players and initiatives by governments for research and development of drugs for managing Alport syndrome and its symptoms are likely to propel the global Alport syndrome market. Hence, faster adoption and availability of diagnostic tests across the globe are anticipated to augment the global Alport syndrome market. However, low awareness about the syndrome and its lower diagnosis rates in underdeveloped countries act as major restraints of the global Alport syndrome market.

Get a Glimpse of the In-Depth Analysis through our Comprehensive “Alport Syndrome Market” Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=73609

North America to Lead Global Alport Syndrome Market

  • In terms of region, the global Alport syndrome market can be divided into: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
  • North America dominated the global Alport syndrome market owing to the increase in incidence of the condition, advanced health care system, and presence of diagnostics companies. Additionally, advanced diagnostic tests and broad network of laboratories are anticipated to fuel the growth of the Alport syndrome market in North America. According to the Alport Syndrome Foundation, Alport syndrome affected around 200,000 people in the U.S. in 2017. Moreover, the syndrome is estimated to affect around 1 in 5,000 to 10,000 people in the country, which is 30,000 to 60,000 people. Moreover, Alport syndrome is estimated to affect around 3% of children with chronic kidney disease (CKD) and 0.2% of adults with end stage renal disease (ESRD). These factors drive demand for early diagnosis, development of advanced genetic testing kits, and faster adoption of skin and kidney biopsy for Alport syndrome. Moreover, robust research & development and rich product pipelines of the major players are likely to propel the Alport syndrome market in the region.
  • Europe was the second largest market for Alport syndrome diagnostics in 2018, followed by Asia Pacific. Clinical trials by key players and availability of advanced diagnostic tests for Alport syndrome are likely to augment the Alport syndrome market in Europe. Approval of Bardoxolone methyl by the EMA in May 2018 for chronic kidney disease, a symptom of Alport syndrome substantiates the fast track approval in Europe. Asia Pacific is projected to be the fastest growing market for Alport syndrome diagnostics. Developing health care facilities, rise in awareness, and development of diagnostic kits such as genetic tests, kidney biopsy, and other blood tests are anticipated to augment the Alport syndrome market in Asia Pacific.

Pre Book “Alport Syndrome Market” Research Report @ https://www.transparencymarketresearch.com/checkout.php?rep_id=73609&ltype=S

Key Manufacturers Operating in Global Alport Syndrome Market

The global Alport syndrome market is highly fragmented. Key players in the global Alport syndrome market are:

  • Illumina, Inc.
  • Merck KGaA (Sigma-Aldrich, Inc.)
  • PerkinElmer, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Centogene AG
  • Myriad Women’s Health, Inc.
  • Quest Diagnostics
  • Others

More Trending Reports by Transparency Market Research –

Insulin Pen Needles Market: prnewswire.com/news-releases/insulin-pen-needles-market-to-expand-at-a-cagr-of-8-0-till-2026-rising-need-for-therapeutic-gadgets-to-augment-global-industry—tmr-300855783.html

Bioremediation Technology & Services Market: prnewswire.com/news-releases/bioremediation-technology—services-market-to-reach-us657-bn-by-2025-globally-transparency-market-research-668429603.html

0 votes

Transparency Market Research (TMR) has published a new report titled, “Cardiac Arrest Treatment Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019–2027”. According to the report, the global cardiac arrest treatment market was valued at US$ 2,650.0 Mn in 2018 and is projected to expand at a CAGR of 4.4% from 2019 to 2027. The global market is driven by increase in awareness & acceptance of cardiac arrest treatment and rise in prevalence rate of sudden cardiac arrest.

The global cardiac arrest treatment market has been segmented based on treatment, sales channel, and region. In terms of treatment, the market has been categorized into drugs and medical devices. The drugs segment has been classified into vasopressors, anti-arrhythmic drugs, anticholinergic drugs, corticosteroids, fibrinolytic drugs, beta blockers, and others (sodium bicarbonate, crystalloids, colloids, etc.). The medical devices segment has been divided into defibrillators, cardiac resynchronization therapy (CRT), and others. Based on sales channel, the global cardiac arrest treatment market has been classified into hospitals, independent pharmacies, and others.

The global cardiac arrest treatment market is driven by increase in incidence of cardiovascular diseases, rapidly aging baby boomer population, and rise in availability of emergency medical services centers. Awareness campaigns by government and non-profitable organizations have resulted in modest, yet steady growth of the global market. The Government of British Columbia (B.C.) in collaboration with the Heart & Stroke Foundation and the American Heart Association & Cardiac Society of Australia New Zealand has come up with various campaigns and training programs to spread awareness about the importance of defibrillators during sudden cardiac arrest. 

Request a PDF Sample – https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=61416

Increase in Incidence of Cardiovascular Diseases and Rise in Geriatric Population to Boost Demand for Cardiac Arrest Treatment

Cardiovascular diseases (CVD) are the major cause of death across the world and account for higher number of deaths than those caused by cancer and AIDS in the U.S. and some countries in Europe. CVDs account for over 17.6 million deaths across the globe each year and the number is expected to reach to 23.6 million by 2030. According to the Heart Rhythm Society, of the 300,000 deaths in the U.S., 75% people have had a prior cardiac arrest experience and 80% have had symptoms of coronary artery disease. Globally, primary causes of sudden cardiac arrest include increase in incidence of obesity, smoking, physical inactivity, diabetes, and unhealthy diet.

Increase in the geriatric population is a major driver of the global cardiac arrest treatment market. Elderly individuals increase the patient pool in major regions of the world. According to World Health Organization (WHO) estimates, the global geriatric population is likely to reach 2 billion (22% of the global population) by 2050, which was around 962 million in 2017. The global geriatric population is expected to increase at the fastest rate in developed countries such as the U.S., the U.K., and Japan.

Brazil, China, Thailand, and South Korea are expected to have a large geriatric population in the shortest span of time in the near future. This increase in the geriatric population is anticipated to boost the growth of the market, as the population is more prone to various age-related as well as chronic diseases. The need of cardiac arrest treatment among such patients is relatively higher, which increases demand for advanced cardiac arrest treatment.

Defibrillators Sub-segment to Grow at a Rapid Pace

The report offers detailed segmentation of the global cardiac arrest treatment market based on treatment and sales channel. The defibrillators sub-segment is expected to expand at a significant CAGR during the forecast period. Increase in the global geriatric population and rise in incidence and prevalence of sudden cardiac arrest are projected to boost the sub-segment from 2019 to 2027. Additionally, rise in disposable income is anticipated to increase the number sudden cardiac arrest patients owing to sedentary lifestyle. However, slow replacement demand for branded automated external defibrillators for sudden cardiac arrest and low availability of automated external defibrillators in emerging countries are anticipated to restrain the defibrillators sub-segment during the forecast period

North America Dominated Global Cardiac Arrest Treatment Market

North America was the leading market for cardiac arrest treatment in 2018. According to the National Conference of State Legislatures, around 250,000 people in North America succumb to sudden cardiac arrest (SCA). In North America, acceptance of medical devices such as defibrillators and cardiac resynchronization therapy (CRT) has increased in the past few years. These factors are projected to contribute to the growth of the cardiac arrest treatment market in the region. 

Buy Now Cardiac Arrest Treatment Market Research Report @ https://www.transparencymarketresearch.com/checkout.php?rep_id=61416&ltype=S

Key Players Operating in Global Cardiac Arrest Treatment Market

The report also provides profiles of leading players operating in the global cardiac arrest treatment market. These include Amgen, Inc., Pfizer, Inc., Johnson & Johnson, Novartis AG, Bristol-Myers Squibb Company, Abbott, Bayer AG, Koninklijke Philips N.V., GE Healthcare, Physio-Control, Inc. (Stryker), Boston Scientific Corporation, Cardiac Science Corporation (Aurora Capital Group), and Shenzhen Mindray Bio-Medical Electronics Co., Ltd.

More Trending Reports by Transparency Market Research –

Hearing Aids Market: prnewswire.com/news-releases/hearing-aids-market-increasing-prevalence-of-hearing-loss-worldwide-augments-product-demand-says-tmr-300857268.html

Global Wound Healing Market: prnewswire.com/news-releases/global-wound-healing-market-to-reach-over-us-350-billion-by-2025-says-tmr-676809663.html

0 votes

Global Nephrostomy Market: Overview    

Nephrostomy surgical procedure is used to remove blockage from the kidney. The global nephrostomy market is expected to grow in the near future. This is mainly due to factors such as increasing incidence of lifestyle related diseases, technological advancement and improving health care infrastructure. Apart from this, rise in geriatric population is also projected to contribute to the growth of the global nephrostomy market. 

The global nephrostomy market can be divided based on end user, product type and geography. Based on end user, the global nephrostomy market can be classified into specialty clinics, hospitals and ambulatory surgical centers. Among all of them hospital segment are anticipated to hold key shares in the market. This is mainly due to the availability of skilled personnel in hospitals. Based on product type, the global nephrostomy market can be categorized into nephrostomy tubes, catheters, sheath dilators, needles, leading wires, retrieval devices, percutaneous access and drainage devices and others.

Request Report Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=49374

Global Nephrostomy Market: Market Potential and Key Trends 

One of the major drivers of the global nephrostomy market is high adoption of minimally invasive surgical procedure. In addition to this, the rise in the reimbursement coverage of  kidney diseases in private and government insurance is a major factor boosting the global nephrostomy market. Owing to this, patients have fewer difficulties pertaining to high cost of the procedure. Apart from this, rise in educational workshop to train urologists to hone skills required for nephrostomy is aiding the nephrostomy market. Despite so many drivers, rising awareness of side effects of the procedure are expected to hinder growth of the market. Some of common side effects are post surgery infection, hemorrhage and tube dislodgement. Nevertheless, lesser operation time as compared to open surgery is expected to boost the global nephrostomy market. 

Global Nephrostomy Market: Geographical Outlook 

The global nephrostomy market is divided into five regions, namely, North America, Asia Pacific, Europe, Latin America, and the Middle East & Africa. Among all of them, North America is projected to dominate the global nephrostomy market in terms of revenue over the forecast period. This is mainly due to the presence of key players, and easy availability of complex surgeries procedure in the region. Increasing investment by several governments in the region for research and development of advanced equipment and procedure is expected to propel growth of the global nephrostomy market. Asia Pacific, is projected to witness high growth in the upcoming years. This is mainly due to the rising prevalence of kidney diseases in the region.

Pre Book This Research Report @ https://www.transparencymarketresearch.com/checkout.php?rep_id=49374&ltype=S

Global Nephrostomy Market: Competitive Landscape 

The global nephrostomy market depicts a highly competitive and fragmented vendor landscape. This is mainly due to the presence of several big and small players in the global market. Key players operating in the global nephrostomy market include Stryker, Cook, C. R. Bard, Inc., Medtronic, Boston Scientific Corporation, Dornier MedTech, UreSil, LLC, Rocamed, and Amecath.

More Trending Reports by Transparency Market Research –

Tissue Engineered Skin Substitutes Market: globenewswire.com/news-release/2019/01/23/1704315/0/en/Tissue-Engineered-Skin-Substitutes-Market-to-reach-around-US-3-87-billion-by-2023-TMR.html

Collagen Market: globenewswire.com/news-release/2019/05/15/1825247/0/en/Collagen-Market-to-Expand-at-a-CAGR-of-9-4-by-2023-Marine-Collagen-to-Gain-Maximum-Prominence-Says-TMR.html

...